Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Market Dynamics
- Emerging Trends
- Analysis by Segment
- Analysis by Region
- Conclusion
Chapter 2 Market Overview
- Substance Use Disorder Overview
- Analysis of Macroeconomic Factors
- Government Funding and Public Healthcare Budgets
- Income Inequality and Socioeconomic Status
- Labor Market Dynamics
- Global Supply Dynamics and the Macroeconomics of Illicit Markets
- Impact of U.S. Tariffs
- Porter’s Five Forces Analysis
- Bargaining Power of Buyers: High
- Bargaining Power of Suppliers: Low to Moderate
- Threat of New Entrants: Moderate
- Threat of Substitutes: Moderate
- Industry Rivalry: High
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Widespread Global Prevalence of Substance Use Disorders
- Proliferation of Illicit Drugs
- Increasing Awareness of the Clinical Impact of Substance Use Disorders
- Increasing Government and Public Health Interventions
- Market Challenges
- Low Treatment Penetration Despite High Disease Burden
- Stigma and Social Barriers
- Market Trends
- Shift Toward Long-Acting and Sustained-Release Therapies
- Innovation in Drug Development
- Expansion of Telemedicine
- Digital-Pharmacologic Combination Therapies
Chapter 4 Regulatory Landscape
- Overview
- U.S.
- Key Federal Actors and Their Roles
- Europe
- European Medicines Agency (EMA)
- The European Union Drugs Agency (EUDA)
- Japan
Chapter 5 Emerging Technologies and Developments
- Emerging Technologies and Developments
- Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs)
- Psychedelics
- Clinical Trial Analysis
- By Condition Type
- By Funder Type
- Therapeutic Candidates in Late-Stage Clinical Trials
Chapter 6 Market Segmentation Analysis
- Segmentation Breakdown
- Global Substance Use Disorder Treatment Market
- Nicotine Use Disorder
- Nicotine Replacement Therapy
- Varenicline
- Others
- Opioid Use Disorder
- Buprenorphine
- Methadone
- Naltrexone
- Alcohol Use Disorder
- Naltrexone
- Acamprosate
- Others
- Geographic Breakdown
- Global Substance Use Disorder Treatment Market, by Region
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South America
Chapter 7 Competitive Intelligence
- Opioid Use Disorder
- Alcohol Use Disorder
- Nicotine Use Disorder
Chapter 8 Sustainability in Substance Use Disorder Treatment Market: An ESG Perspective
- Introduction to ESG
- Key ESG Issues Specific to the Substance Use Disorder Treatment Market
- Closing the Treatment Gap
- Community Engagement and Stigma Reduction
- Carbon Footprint Reduction
- Data Transparency and Outcomes Reporting
- Concluding Remarks
List of Tables
Summary Table: Global Market for Substance Use Disorder Treatment, by Region, Through 2030
Table 1: Substance Use Disorders Prevalence for Key Substances in the U.S., 2023
Table 2: The Substance Use Treatment Gap in the U.S., 2024
Table 3: Therapeutic Candidates in Phase 3 for Nicotine Use Disorder or Alcohol Use Disorder
Table 4: Therapeutic Candidates in Phase 2 for Opioid Use Disorder
Table 5: Therapeutic Candidates in Phase 2 for Alcohol Use Disorder
Table 6: Therapeutic Candidates in Phase 2 for Nicotine Use Disorder
Table 7: Industry-Sponsored Therapeutic Candidates in Phase 2 for Cannabis Use Disorder
Table 8: Industry-Sponsored Therapeutic Candidates in Phase 2 for Methamphetamine Use Disorder
Table 9: Drug Classes Commonly Associated with Substance-Related Disorders
Table 10: Global Market for Substance Use Disorder Treatment, by Condition, Through 2030
Table 11: Global Market for Nicotine Use Disorder Treatment, by Drug Type, Through 2030
Table 12: NRT Products
Table 13: Global Market for Opioid Use Disorder Treatment, by Drug Type, Through 2030
Table 14: FDA-Approved Buprenorphine Medications for Opioid Use Disorder (MOUD)
Table 15: OUD Medications: An Overview
Table 16: Global Market for Alcohol Use Disorder Treatment, by Drug Type, Through 2030
Table 17: Alcohol Use Disorder Medications: An Overview
Table 18: Global Market for Substance Use Disorder Treatment, by Region, Through 2030
Table 19: North American Market for Substance Use Disorder Treatment, by Condition, Through 2030
Table 20: North American Market for Substance Use Disorder Treatment, by Country, Through 2030
Table 21: Substance Use Among the General Population in Canada, 2023
Table 22: European Market for Substance Use Disorder Treatment, by Condition, Through 2030
Table 23: European Market for Substance Use Disorder Treatment, by Country, Through 2030
Table 24: Share of Adults Who Smoked in 2000 versus 2024 Trends in Prevalence of Tobacco Use Among People Aged 15 Years and Older, by WHO Region
Table 25: Adult Substance Misuse Treatment Statistics in the U.K., 2023-2024
Table 26: Asia-Pacific Market for Substance Use Disorder Treatment, by Condition, Through 2030
Table 27: Asia-Pacific Market for Substance Use Disorder Treatment, by Country, Through 2030
Table 28: Middle East and African Market for Substance Use Disorder Treatment, by Condition, Through 2030
Table 29: Share of Population with Alcohol Use Disorder (2021) versus Drug Use Disorder (2021) versus Smoke or Tobacco Users (2022)
Table 30: South American Market for Substance Use Disorder Treatment, by Condition, Through 2030
Table 31: Information Sources for this Report
Table 32: Abbreviations Used in This Report
Table 33: Achieve Life Sciences Inc.: Company Snapshot
Table 34: Achieve Life Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 35: Achieve Life Sciences Inc.: Product Portfolio
Table 36: Achieve Life Sciences Inc.: News/Key Developments, 2024-2025
Table 37: Adial Pharmaceuticals: Company Snapshot
Table 38: Adial Pharmaceuticals: Financial Performance, FY 2023 and 2024
Table 39: Adial Pharmaceuticals: Product Portfolio
Table 40: Adial Pharmaceuticals: News/Key Developments, 2025
Table 41: Alkermes: Company Snapshot
Table 42: Alkermes: Financial Performance, FY 2023 and 2024
Table 43: Alkermes: Product Portfolio
Table 44: Braeburn Inc.: Company Snapshot
Table 45: Braeburn Inc.: Product Portfolio
Table 46: Camurus AB: Company Snapshot
Table 47: Camurus AB: Financial Performance, FY 2023 and 2024
Table 48: Camurus AB: Product Portfolio
Table 49: Camurus AB: News/Key Developments, 2025
Table 50: Da-pharma: Company Snapshot
Table 51: Da-pharma: Product Portfolio
Table 52: Dr. Reddy’s Laboratories Ltd.: Company Snapshot
Table 53: Dr. Reddy’s Laboratories Ltd.: Financial Performance, FY 2023 and 2024
Table 54: Dr. Reddy’s Laboratories Ltd.: Product Portfolio
Table 55: Dr. Reddy’s Laboratories Ltd.: News/Key Developments, 2025
Table 56: Ethypharm: Company Snapshot
Table 57: Ethypharm: Product Portfolio
Table 58: H. Lundbeck A/S: Company Snapshot
Table 59: H. Lundbeck A/S: Financial Performance, FY 2023 and 2024
Table 60: H. Lundbeck A/S: Product Portfolio
Table 61: Indivior PLC: Company Snapshot
Table 62: Indivior PLC: Financial Performance, FY 2023 and 2024
Table 63: Indivior PLC: Product Portfolio
Table 64: Indivior PLC: News/Key Developments, 2025
Table 65: Kenvue: Company Snapshot
Table 66: Kenvue: Financial Performance, FY 2023 and 2024
Table 67: Kenvue: Product Portfolio
Table 68: Lilly USA LLC.: Company Snapshot
Table 69: Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 70: Lilly USA LLC.: Product Portfolio
Table 71: NFL Biosciences: Company Snapshot
Table 72: NFL Biosciences: Financial Performance, FY 2023 and 2024
Table 73: NFL Biosciences: Product Portfolio
Table 74: NFL Biosciences: News/Key Developments, 2025
Table 75: Orexo AB (Publ.): Company Snapshot
Table 76: Orexo AB (Publ.): Financial Performance, FY 2023 and 2024
Table 77: Orexo AB (Publ.): Product Portfolio
Table 78: Orexo AB (Publ.): News/Key Developments, 2024-2025
Table 79: Par Health Inc.: Company Snapshot
Table 80: Par Health Inc.: Product Portfolio
Table 81: Emerging Startups/Market Disruptors
List of Figures
Summary Figure: Global Market Shares for Substance Use Disorder Treatment, by Region, 2024
Figure 1: Porter’s Five Forces Analysis-Substance Use Disorder Treatment Industry
Figure 2: Market Dynamics of Substance Use Disorder Treatment
Figure 3: Active Clinical Trials of Substance Use Disorders, by Condition, 2025
Figure 4: Active Clinical Trials of Substance Use Disorders, by Funder Type, 2025
Figure 5: Global Market Shares for Substance Use Disorder Treatment, by Condition, 2024
Figure 6: Global Market Shares for Nicotine Use Disorder Treatment, by Drug Type, 2024
Figure 7: Global Market Shares for Opioid Use Disorder Treatment, by Drug Type, 2024
Figure 8: Global Market Shares for Alcohol Use Disorder Treatment, by Drug Type, 2024
Figure 9: Global Market Shares for Substance Use Disorder Treatment, by Region, 2024
Figure 10: North American Market Shares for Substance Use Disorder Treatment, by Condition, 2024
Figure 11: North American Market Shares for Substance Use Disorder Treatment, by Country, 2024
Figure 12: Number of Americans Aged 12 or Older Using Cigarette or Nicotine Vaping Products
Figure 13: European Market Shares for Substance Use Disorder Treatment, by Condition, 2024
Figure 14: European Market Shares for Substance Use Disorder Treatment, by Country, 2024
Figure 15: People in Opioid Agonist Treatment in the EU in 2023, by Type of Medication
Figure 16: Total Number of Adults Receiving Treatment for Drugs and/or Alcohol in England
Figure 17: Asia-Pacific Market Shares for Substance Use Disorder Treatment, by Condition, 2024
Figure 18: Asia-Pacific Market Shares for Substance Use Disorder Treatment, by Country, 2024
Figure 19: Middle East and African Market Shares for Substance Use Disorder Treatment, by Condition, 2024
Figure 20: South American Market Shares for Substance Use Disorder Treatment, by Condition, 2024
Figure 21: Global Market Shares for Opioid Use Disorder Treatment Market, by Company, 2024
Figure 22: ALKERMES: Revenue Shares, by Business Unit, FY 2024
Figure 23: ALKERMES: Revenue Shares, by Country/Region, FY 2024
Figure 24: Camurus AB: Revenue Shares, by Business Unit, FY 2024
Figure 25: Camurus AB: Revenue Shares, by Country/Region, FY 2024
Figure 26: Dr. Reddy’s Laboratories Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 27: Dr. Reddy’s Laboratories Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 28: H. Lundbeck A/S: Revenue Shares, by Business Unit, FY 2024
Figure 29: H. Lundbeck A/S: Revenue Shares, by Country/Region, FY 2024
Figure 30: Indivior PLC: Revenue Shares, by Business Unit, FY 2024
Figure 31: Indivior PLC: Revenue Shares, by Country/Region, FY 2024
Figure 32: KENVUE: Revenue Shares, by Business Unit, FY 2024
Figure 33: KENVUE: Revenue Shares, by Country/Region, FY 2024
Figure 34: Lilly USA LLC.: Revenue Shares, by Business Unit, FY 2024
Figure 35: Lilly USA LLC.: Revenue Shares, by Country/Region, FY 2024
Figure 36: Orexo AB (Publ.): Revenue Shares, by Business Unit, FY 2024
Figure 37: Orexo AB (Publ.): Revenue Shares, by Country/Region, FY 2024
